• 1
    Chikritzh T, Jonas H, Heale P et al. National Alcohol Indicators Project (Technical Report No. 1: Alcohol-caused Deaths and Hospitalisations in Australia 1990–97). Perth: National Drug and Alcohol Research Centre, 2000.
  • 2
    Hill DB, Deaciuc IV, Nanji AA et al. Mechanisms of hepatic injury in alcoholic liver disease. Clin. Liver Dis. 1998; 3: 70321.
  • 3
    Haber PS, Gentry RT, Mak KM et al. Metabolism of alcohol by human gastric cells: relation to first-pass metabolism. Gastroenterology 1996; 111: 86370.
  • 4
    Hoek JB, Thomas AP, Rooney TA et al. Ethanol and signal transduction in the liver. FASEB J. 1992; 6: 238696.
  • 5
    Hoek JB, Kholodenko BN. The intracellular signaling network as a target for ethanol. Alcohol Clin. Exp. Res. 1998; 22: 22430S.
  • 6
    Yamada S, Mak KM, Lieber CS. Chronic ethanol consumption alters rat liver plasma membranes and potentiates release of alkaline phosphatase. Gastroenterology 1985; 88: 1799806.
  • 7
    Lieber CS. Hepatic and metabolic effects of ethanol: pathogenesis and prevention. Ann. Med. 1994; 26: 32530.
  • 8
    Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol. Rev. 1997; 77: 51744.
  • 9
    Lieber CS. The microsomal ethanol oxidizing system: its role in ethanol and xenobiotic metabolism. Biochem. Soc. Trans. 1988; 16: 2329.
  • 10
    Lieber CS, Leo MA. Alcohol and the liver. In: LieberCS, ed. Medical and Nutritional Complications of Alcoholism. New York: Plenum, 1992; 185239.
  • 11
    Yokoyama H, Nagata S, Moriya S et al. Hepatic fibrosis produced in guinea pigs by chronic ethanol administration and immunization with acetaldehyde adducts. Hepatology 1995; 21: 143842.
  • 12
    Svegliati-Baroni G, Baraona E, Rosman AS et al. Collagen-acetaldehyde adducts in alcoholic and nonalcoholic liver diseases. Hepatology 1994; 20: 11118.
  • 13
    Enomoto N, Takase S, Takada N et al. Alcoholic liver disease in heterozygotes of mutant and normal aldehyde dehydrogenase-2 genes. Hepatology 1991; 13: 10715.
  • 14
    Korsten MA, Matsuzaki S, Feinman L et al. High blood acetaldehyde levels after ethanol administration. Difference between alcoholic and nonalcoholic subjects. N. Engl. J. Med. 1975; 292: 3869.
  • 15
    Fernandez-Checa JC, Kaplowitz N, Garcia-Ruiz C et al. GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Am. J. Physiol. 1997; 273: G717.
  • 16
    Leo MA, Rosman AS, Lieber CS. Differential depletion of carotenoids and tocopherol in liver disease. Hepatology 1993; 17: 97786.
  • 17
    Kawase T, Kato S, Lieber CS. Lipid peroxidation and antioxidant defense systems in rat liver after chronic ethanol feeding. Hepatology 1989; 10: 81521.
  • 18
    Fiorelli G, De Feo TM, Duca L et al. Red blood cell antioxidant and iron status in alcoholic and nonalcoholic cirrhosis. Eur. J. Clin. Invest. 2002; 32 (Suppl. 1): 217.
  • 19
    Cederbaum AI. Effects of alcohol on hepatic mitochondrial function and DNA. Gastroenterology 1999; 117: 2659.
  • 20
    Colell A, Garcia-Ruiz C, Miranda M et al. Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. Gastroenterology 1998; 115: 154151.
  • 21
    Schletter J, Heine H, Ulmer AJ et al. Molecular mechanisms of endotoxin activity. Arch. Microbiol. 1995; 164: 3839.
  • 22
    Su GL, Klein RD, Aminlari A et al. Kupffer cell activation by lipopolysaccharide in rats: role for lipopolysaccharide binding protein and toll-like receptor 4. Hepatology 2000; 31: 9326.
  • 23
    Modlin RL, Brightbill HD, Godowski PJ. The toll of innate immunity on microbial pathogens. N. Engl. J. Med. 1999; 340: 18345.
  • 24
    Bradham CA, Plumpe J, Manns MP et al. Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am. J. Physiol. 1998; 275: G38792.
  • 25
    Bode C, Kugler V, Bode JC. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J. Hepatol. 1987; 4: 814.
  • 26
    Enomoto N, Ikejima K, Bradford B et al. Alcohol causes both tolerance and sensitization of rat Kupffer cells via mechanisms dependent on endotoxin. Gastroenterology 1998; 115: 44351.
  • 27
    Bhagwandeen BS, Apte M, Manwarring L et al. Endotoxin induced hepatic necrosis in rats on an alcohol diet. J. Pathol 1987; 152: 4753.
  • 28
    Adachi Y, Moore LE, Bradford BU et al. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995; 108: 21824.
  • 29
    Uesugi T, Froh M, Arteel GE et al. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 2001; 34: 1018.
  • 30
    McClain C, Hill D, Schmidt J et al. Cytokines and alcoholic liver disease. Semin. Liver Dis. 1993; 13: 17082.
  • 31
    Hanck C, Rossol S, Bocker U et al. Presence of plasma endotoxin is correlated with tumour necrosis factor receptor levels and disease activity in alcoholic cirrhosis. Alcohol Alcohol. 1998; 33: 6068.
  • 32
    Akriviadis E, Botla R, Briggs W et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 163748.
  • 33
    Yin M, Wheeler MD, Kono H et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999; 117: 94252.
  • 34
    Maher JJ, Bissell DM, Friedman SL et al. Collagen measured in primary cultures of normal rat hepatocytes derives from lipocytes within the monolayer. J. Clin. Invest. 1988; 82: 4509.
  • 35
    Apte MV, Haber PS, Applegate TL et al. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut 1998; 43: 12833.
  • 36
    Friedman SL, Wei S, Blaner WS. Retinol release by activated rat hepatic lipocytes: regulation by Kupffer cell-conditioned medium and PDGF. Am. J. Physiol. 1993; 264: G94752.
  • 37
    Reeves HL, Burt AD, Wood S et al. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J. Hepatol. 1996; 25: 67783.
  • 38
    Iredale JP, Benyon RC, Pickering J et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J. Clin. Invest. 1998; 102: 53849.
  • 39
    Streetz KL, Luedde T, Manns MP et al. Interleukin 6 and liver regeneration. Gut 2000; 47: 30912.
  • 40
    Yavorkovsky L, Lai E, Ilic Z et al. Participation of small intraportal stem cells in the restitutive response of the liver to periportal necrosis induced by allyl alcohol. Hepatology 1995; 21: 170212.
  • 41
    Diehl AM. Alcohol and liver regeneration. Clin. Liver Dis. 1998; 2: 72338.
  • 42
    Yang SQ, Lin HZ, Yin M et al. Effects of chronic ethanol consumption on cytokine regulation of liver regeneration. Am. J. Physiol. 1998; 275: G696704.
  • 43
    Zhang BH, Farrell GC. Effects of extracellular Ca2+ and HCO3- on epidermal growth factor-induced DNA synthesis in cultured rat hepatocytes. Gastroenterology 1995; 108: 47786.
  • 44
    Zhang BH, Hornsfield BP, Farrell GC. Chronic ethanol administration to rats decreases receptor-operated mobilization of intracellular ionic calcium in cultured hepatocytes and inhibits 1,4,5-inositol trisphosphate production: relevance to impaired liver regeneration. J. Clin. Invest. 1996; 98: 123744.
  • 45
    Mohr L, Tanaka S, Wands JR. Ethanol inhibits hepatocyte proliferation in insulin receptor substrate 1 transgenic mice. Gastroenterology 1998; 115: 155865.
  • 46
    Hrubec Z, Omenn GS. Evidence of genetic predisposition to alcoholic cirrhosis and psychosis: twin concordance for alcoholism and its end points by zygosity among male veterans. Alcohol. Clin. Exp. Res. 1981; 5: 20715.
  • 47
    Grove J, Daly AK, Bassendine MF et al. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997; 26: 1436.
  • 48
    Day CP. Who gets alcoholic liver disease: nature or nurture? J. R. Coll. Physicians Lond. 2000; 34: 55762.
  • 49
    Norton R, Batey R, Dwyer T et al. Alcohol consumption and the risk of alcohol related cirrhosis in women. Br. Med. J. (Clin. Res. Ed.) 1987; 295: 802.
  • 50
    Frezza M, Di Padova C, Pozzato G et al. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N. Engl. J. Med. 1990; 322: 959.
  • 51
    Kwo PY, Ramchandani VA, O'Connor S et al. Gender differences in alcohol metabolism: relationship to liver volume and effect of adjusting for body mass. Gastroenterology 1998; 115: 15527.
  • 52
    Iimuro Y, Frankenberg MV, Arteel GE et al. Female rats exhibit greater susceptibility to early alcohol-induced liver injury than males. Am. J. Physiol. 1997; 272: G118694.
  • 53
    Schiff ER. Hepatitis C and alcohol. Hepatology 1997; 26: 3942S.
  • 54
    Cooksley W. Chronic liver disease: do alcohol and hepatitis C virus interact. J. Gastroenterol. Hepatol. 1996; 11: 18792.
  • 55
    Brechot C. Hepatitis B and C viruses and primary liver cancer. Baillieres Clin. Gastroenterol. 1996; 10: 33573.
  • 56
    Naveau S, Giraud V, Borotto E et al. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25: 10811.
  • 57
    Wootton FT, Lee WM. Acetaminophen hepatotoxicity in the alcoholic. South. Med. J. 1990; 83: 10479.
  • 58
    West SG. Methotrexate hepatotoxicity. Rheum. Dis. Clin. North Am. 1997; 23: 883915.
  • 59
    Mayfield D, McLeod G, Hall P. The CAGE questionnaire: validation of a new alcoholism screening instrument. Am. J. Psychiatry 1974; 131: 11213.
  • 60
    Samet JH, Rollnick S, Barnes H. Beyond CAGE. A brief clinical approach after detection of substance abuse. Arch. Intern. Med. 1996; 156: 228793.
  • 61
    Saunders JB, Assland OG, Babor TF et al. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project early detection persons with harmful alcohol consumption – II. Addiction 1993; 88: 791804.
  • 62
    Moussavian SN, Becker RC, Piepmeyer JL et al. Serum gamma-glutamyl transpeptidase and chronic alcoholism. Influence of alcohol ingestion and liver disease. Dig. Dis. Sci. 1985; 30: 21114.
  • 63
    Conigrave KM, Saunders, JB, Whitfield JB. Diagnostic tests for alcohol consumption. Alcohol Alcohol. 1995; 30: 1316.
  • 64
    Anton RF, Moak DH, Latham P. Carbohydrate-deficient transferrin as an indicator of drinking status during a treatment outcome study. Alcohol. Clin. Exp. Res. 1996; 20: 8416.
  • 65
    Keating J, Cheung C, Peters TJ et al. Carbohydrate deficient transferrin in the assessment of alcohol misuse: absolute or relative measurements? A comparison of two methods with regard to total transferrin concentration. Clin. Chim. Acta 1998; 272: 15969.
  • 66
    De Feo TM, Fargion S, Duca L et al. Carbohydrate-deficient transferrin, a sensitive marker of chronic alcohol abuse, is highly influenced by body iron. Hepatology 1999; 29: 65863.
  • 67
    Scouller K, Conigrave KM, Macaskill P et al. Should we use carbohydrate deficient transferrin instead of gamma-glutamyltransferase for detecting problem drinkers? A systematic review and metaanalysis. Clin. Chem. 2000; 46: 18941902.
  • 68
    Meregalli M, Giacomini V, Lino S et al. Carbohydrate-deficient transferrin in alcohol and nonalcohol abusers with liver disease. Alcohol. Clin. Exp Res. 1995; 19: 15257.
  • 69
    Murawaki Y, Sugisaki H, Yuasa I et al. Serum carbohydrate-deficient transferrin in patients with nonalcoholic liver disease and with hepatocellular carcinoma. Clin. Chim. Acta 1997; 259: 97108.
  • 70
    Halm U, Tannapfel A, Mossner J et al. Relative versus absolute carbohydrate-deficient transferrin as a marker of alcohol consumption in patients with acute alcoholic hepatitis. Alcohol. Clin. Exp. Res. 1999; 23: 161418.
  • 71
    Mathurin P, Duchatelle V, Ramond MJ et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996; 110: 184753.
  • 72
    Chedid A, Mendenhall CL, Gartside P et al. Prognostic factors in alcoholic liver disease. VA Cooperative Study Group. Am. J. Gastroenterol. 1991; 86: 21016.
  • 73
    Galambos JT. Alcoholic hepatitis: its therapy and prognosis. Prog. Liver Dis. 1972; 4: 56788.
  • 74
    Soterakis J, Resnik RH, Iber FL. Effect of alcohol abstinence on survival in cirrhotic portal hypertension. Lancet 1973; II: 657.
  • 75
    Borowsky SA, Strome S, Lott E. Continued heavy drinking and survival in alcoholic cirrhotics. Gastroenterology 1981; 80: 14059.
  • 76
    Saunders JB, Davis M, Williams R. Do women develop alcoholic liver disease more readily than men? Br. Med. J. (Clin. Res. Ed.) 1981; 282: 11403.
  • 77
    Pares A, Caballeria J, Bruguera M et al. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J. Hepatol. 1986; 2: 3342.
  • 78
    Rosman AS, Waraich A, Galvin K et al. Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. Am. J. Gastroenterol. 1996; 91: 498505.
  • 79
    Caldwell SH, Jeffers LJ, Ditomaso A et al. Antibody to hepatitis C is common among patients with alcoholic liver disease with and without risk factors. Am. J. Gastroenterol. 1991; 86: 121923.
  • 80
    Mendenhall CL, Seeff L, Diehl AM et al. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. The VA Cooperative Study Group (no. 119). Hepatology 1991; 14: 5819.
  • 81
    Mendenhall C. Alcoholic hepatitis. In: SchiffER, ed. Diseases of the Liver. Philadelphia: Lippincott, 1993; 85674.
  • 82
    Talley NJ, Roth A, Woods J et al. Diagnostic value of liver biopsy in alcoholic liver disease. J. Clin. Gastroenterol. 1988; 10: 64750.
  • 83
    Hill DB, Marsano LS, McClain CJ. Increased plasma interleukin-8 concentrations in alcoholic hepatitis. Hepatology 1993; 18: 57680.
  • 84
    Spahr L, Rubbia-Brandt L, Pugin J et al. Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. J. Hepatol. 2001; 35: 5829.
  • 85
    Garbutt JC, West SL, Carey TS et al. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999; 281: 131825.
  • 86
    Bien TH, Miller WR, Tonigan JS. Brief interventions for alcohol problems: a review. Addiction 1993; 88: 31535.
  • 87
    Jarvis T, Tebbutt J, Mattick R. Treatment approaches for alcohol and drug dependence. An introductory guide. Chichester, England: John Wiley & Sons Ltd, 1995; 225.
  • 88
    Sax DS, Kornetsky C, Kim A. Lack of hepatotoxicity with naltrexone treatment. J. Clin. Pharmacol. 1994; 34: 898901.
  • 89
    Bertolotti M, Ferrari A, Vitale G et al. Effect of liver cirrhosis on the systemic availability of naltrexone in humans. J. Hepatol. 1997; 27: 50511.
  • 90
    Sass H, Soyka M, Mann K et al. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch. Gen. Psychiatry 1996; 53: 67380.
  • 91
    Saivin S, Hulot T, Chabac S et al. Clinical pharmacokinetics of acamprosate. Clin. Pharmacokinet. 1998; 35: 33145.
  • 92
    McGrady BS. Recent research in twelve step programs. In: GrahamAW, SchultzTK, eds. Principles of Addiction Medicine, 2nd edn. Chevy Chase, Maryland, USA: American Society of Addiction Medicine, 1998; 95568.
  • 93
    Baraona E, Julkunen R, Tannenbaum L et al. Role of intestinal bacterial overgrowth in ethanol production and metabolism in rats. Gastroenterology 1986; 90: 10310.
  • 94
    Helander A, Carlsson AV, Borg S. Longitudinal comparison of carbohydrate-deficient transferrin and gamma-glutamyl transferase: complementary markers of excessive alcohol consumption. Alcohol Alcohol. 1996; 31: 1017.
  • 95
    Whitfield JB. Gamma glutamyl transferase. Crit. Rev. Clin. Lab. Sci. 2001; 38: 263355.
  • 96
    Shaw S, Worner TM, Borysow MF et al. Detection of alcoholism relapse: comparative diagnostic value of MCV, GGTP, and AANB. Alcohol. Clin. Exp. Res. 1979; 3: 297301.
  • 97
    Rosman AS, Basu P, Galvin K et al. Utility of carbohydrate-deficient transferrin as a marker of relapse in alcoholic patients. Alcohol. Clin. Exp. Res. 1995; 19: 61116.
  • 98
    Morgan MY. The treatment of alcoholic hepatitis. Alcohol Alcohol. 1996; 31: 11734.
  • 99
    Powell LW, Axelsen E. Corticosteroids in liver disease: studies on the biological conversion of prednisone to prednisolone and plasma protein binding. Gut 1972; 13: 6906.
  • 100
    Depew W, Boyer T, Omata M et al. Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology 1980; 78: 5249.
  • 101
    Elenkov IJ, Papanicolaou DA, Wilder RL et al. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proc. Assoc. Am. Physicians 1996; 108: 37481.
  • 102
    Jefferson DM, Reid LM, Giambrone MA et al. Effects of dexamethasone on albumin and collagen gene expression in primary cultures of adult rat hepatocytes. Hepatology 1985; 5: 1420.
  • 103
    Helman RA, Temko MH, Nye SW et al. Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Ann. Intern. Med. 1971; 74: 31121.
  • 104
    McCullough AJ, O'Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am. J. Gastroenterol. 1998; 93: 202236.
    Direct Link:
  • 105
    Mezey E. Interaction between alcohol and nutrition in the pathogenesis of alcoholic liver disease. Semin. Liver Dis. 1991; 11: 3408.
  • 106
    Mendenhall CL, Moritz TE, Roselle GA et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology 1993; 17: 56476.
  • 107
    Calvey H, Davis M, Williams R. Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. J. Hepatol. 1985; 1: 14151.
  • 108
    Nasrallah SM, Galambos JT. Aminoacid therapy of alcoholic hepatitis. Lancet 1980; 2: 12767.
  • 109
    Girolami B, Bernardi E, Prins MH et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch. Intern. Med. 1999; 159: 33745.
  • 110
    Windmeier C, Gressner AM. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen. Pharmacol. 1997; 29: 18196.
  • 111
    Orrego H, Kalant H, Israel Y et al. Effect of short-term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology 1979; 76: 10515.
  • 112
    Orrego H, Blake JE, Blendis LM et al. Long-term treatment of alcoholic liver disease with propylthiouracil. N. Engl. J. Med. 1987; 317: 14217.
  • 113
    Halle P, Pare P, Kaptein E et al. Double-blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology 1982; 82: 92531.
  • 114
    Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database System Review 2001; CD002148.
  • 115
    Akriviadis EA, Steindel H, Pinto PC et al. Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis. Gastroenterology 1990; 99: 81118.
  • 116
    Trinchet JC, Balkau B, Poupon RE et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology 1992; 15: 7681.
  • 117
    Colell A, Garcia-Ruiz C, Morales A et al. Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol-treated rats: effect of membrane physical properties and S-adenosyl-L-methionine. Hepatology 1997; 26: 699708.
  • 118
    Mato JM, Camara J, Fernandez de Paz J et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J. Hepatol. 1999; 30: 10819.
  • 119
    Lieber CS, Leo MA, Aleynik S et al. Increased circulating level of dilinoleoylphosphatidylcholine is associated with protection against alcohol induced oxidative stress and liver fibrosis in man[Abstract]. Hepatology 2000; 32: 386A.
  • 120
    Panos MZ, Polson R, Johnson R. Polyunsaturated phosphatidylcholine for acute alcoholic hepatitis: a double blind randomized placebo controlled trial. Eur. J. Gastroenterol. Hepatol. 1990; 2: 3515.
  • 121
    Steinberg EN. N acetyl cysteine may improve clinical outcome in acute alcoholic hepatitis[Abstract]. Gastroenterology 1996; 110: A1334.
  • 122
    Jalan R, Williams R, Kaser A et al. Clinical and cytokine response to anti-TNF antibody therapy in severe alcoholic hepatitis [Abstract]. Hepatology 2001; 34: 441A.
  • 123
    Neuman MG, Brenner DA, Rehermann B et al. Mechanisms of alcoholic liver disease: cytokines. Alcohol. Clin. Exp. Res. 2001; 25: 2513S.
  • 124
    George J, Roulot D, Koteliansky VE et al. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc. Natl Acad. Sci. USA 1999; 96: 1271924.
  • 125
    Fulton S, McCullough AJ. Treatment of alcoholic hepatitis. Clin. Liver Dis. 1998; 2: 799819.
  • 126
    Kumar S, Stauber RE, Gavaler JS et al. Orthotopic liver transplantation for alcoholic liver disease. Hepatology 1990; 11: 15964.
  • 127
    Everson G, Bharadhwaj G, House R et al. Long-term follow-up of patients with alcoholic liver disease who underwent hepatic transplantation. Liver Transpl. Surg. 1997; 3: 26374.
  • 128
    Haber PS, Koorey DJ, Gribble RJD et al. Clinical outcomes of liver transplantation for alcoholic liver disease [Abstract]. J. Gastroenterol. Hepatol. 1999; 14 (Suppl.): A130.
  • 129
    Neuberger J, Tang H. Relapse after transplantation: European studies. Liver Transpl. Surg. 1997; 3: 2759.
  • 130
    Lucey MR, Merion RM, Henley KS et al. Selection for and outcome of liver transplantation in alcoholic liver disease. Gastroenterology 1992; 102: 173641.
  • 131
    Shakil AO, Pinna A, Demetris J et al. Survival and quality of life after liver transplantation for acute alcoholic hepatitis. Liver Transpl. Surg. 1997; 3: 2404.